ArticleEClinicalMedicine2023

Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.

Xi Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.